Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Clinical Implications

Clinical Implications

Download PDF
https://doi.org/10.1161/HYPERTENSIONAHA.118.10969
Hypertension. 2018;71:539
Originally published March 7, 2018
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Socioeconomic Status and Hypertension in Africa (p 577)
    • Antifibrotic Effects of Finerenone (p 599)
    • MiR-30c-5p Pathway in Cocaine-Induced Hypertension (p 752)
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Socioeconomic Status and Hypertension in Africa (p 577)

Figure1

Systemic hypertension is a rapidly growing epidemic in Africa. Our study represents the first multination report on socioeconomic status and uncontrolled hypertension from Sub-Saharan Africa. Our results demonstrate the overall strikingly high proportion of uncontrolled blood pressure in low- and middle-income countries (77.4%), of which 61.7% had hypertension of grade 2 or 3. We further observed that the rate and severity (hypertension grade) of uncontrolled hypertension was proportional to individual wealth. This was observed in low-income but not middle-income countries, suggesting that the combination of individual poverty with a poor health system is particularly detrimental to achieving the goal of adequate blood pressure control. Hypertension is probably the easiest chronic noncommunicable disease to treat because blood pressure measurement for diagnosis and monitoring is simple, drug regimens are mainly once daily and inexpensive, and treatments generally do not need laboratory monitoring. According to World Health Organization estimations, the African region has the highest prevalence world rate of hypertension, afflicting 46% of the adult population aged ≥25 years. With >9 million deaths from hypertension worldwide each year, the potential effect of improved treatment of hypertension, particularly if combined with population-wide measures, would be substantial. Strategies for improving hypertension control in Sub-Saharan Africa should focus on people belonging to the lowest wealth groups with a particular focus on those living in low-income countries.

Antifibrotic Effects of Finerenone (p 599)

Figure2

In this study, we demonstrate that the new nonsteroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrosis and improves global longitudinal strain parameters in a mouse model of early subendocardial damage. In addition, we identify a new pharmacological mechanism of selective mineralocorticoid receptor modulation which distinguishes nonsteroidal mineralocorticoid receptor antagonists from steroidal mineralocorticoid receptor antagonists based on selective mineralocorticoid receptor–cofactor binding. It has been shown previously by other groups that finerenone also exerts antifibrotic action in the kidney. The efficacy and safety of finerenone in patients with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease is currently being investigated in 2 large phase 3 outcome trials in patients with diabetic kidney disease (FIGARO-DKD [Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease], URL: http://www.clinicaltrials.gov. Unique identifier: NCT02545049; FIDELIO-DKD [Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease], URL: http://www.clinicaltrials.gov. Unique identifier: NCT02540993). FIGARO-DKD is a 6400 patient trial that will examine the time to the first occurrence of the composite end point of cardiovascular death and nonfatal cardiovascular events, whereas FIDELIO-DKD is a 4800 patient trial that will compare the effects of finerenone versus placebo on the time to the first occurrence of the composite end point of kidney failure, decrease of estimated glomerular filtration rate ≥40% from baseline, or renal death. The marked cardiorenal antifibrotic effects of finerenone shown in our study and by others are likely to be substantial for finerenone’s clinical effects currently tested in these trials.

MiR-30c-5p Pathway in Cocaine-Induced Hypertension (p 752)

Figure3

The use of cocaine remains the leading cause for all illicit drug-related emergency department visits, with the majority of these visits resulting from cardiovascular complaints, including chest pain. Cocaine exposure has short-term effects on the cardiovascular system, such as increasing blood pressure and inducing arrhythmias, but also negatively impacts long-term cardiovascular health by increasing the risk for hypertension, aortic stiffness, and atherosclerosis. It is well-known that cocaine inhibits catecholamine reuptake at sympathetic nerve terminals, stimulates central sympathetic outflow, and increases the sensitivity of adrenergic nerve endings to norepinephrine. It has been assumed that these cocaine-associated sympathetic nervous system effects are wholly responsible for hypertension and other cardiovascular effects resulting from cocaine exposure. However, recent studies have suggested that other mechanisms may be governing the effects of cocaine on the cardiovascular system. To better understand the molecular mechanisms underlying cocaine-induced cardiovascular toxicities, we analyzed microRNAs whose expression was altered in mouse aortas in response to cocaine exposure. We have identified a key pathway, the miR-30c–Me1 (malic enzyme 1) axis, that is involved in regulating reactive oxygen species levels, crucial factors in the pathogenesis of hypertension, vascular aging, and atherosclerosis. Inhibition of this pathway suppresses cocaine-induced elevation of blood pressure and augmentation of aortic stiffness in mice, providing new molecular targets for the development of therapeutic strategies as well as the rationale for the use of an antioxidant, such as N-acetylcysteine, to treat cocaine-associated cardiovascular toxicities.

  • © 2018 American Heart Association, Inc.
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
April 2018, Volume 71, Issue 4
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Socioeconomic Status and Hypertension in Africa (p 577)
    • Antifibrotic Effects of Finerenone (p 599)
    • MiR-30c-5p Pathway in Cocaine-Induced Hypertension (p 752)
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Clinical Implications
    Hypertension. 2018;71:539, originally published March 7, 2018
    https://doi.org/10.1161/HYPERTENSIONAHA.118.10969

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Clinical Implications
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Clinical Implications
    Hypertension. 2018;71:539, originally published March 7, 2018
    https://doi.org/10.1161/HYPERTENSIONAHA.118.10969
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured